TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Trial of Microplasmin Intravitreal Injection for Non-surgical Treatment of Focal Vitreomacular Adhesion. The MIVI-TRUST (TG-MV-006) Trial.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Presence of focal vitreomacular adhesion (i.e., central vitreal adhesion within 6mm Optical Coherence Tomography (OCT) field surrounded by elevation of the posterior vitreous cortex) that in the opinion of the Investigator is related to decreased visual function (such as metamorphopsia, decreased visual acuity, or other visual complaint)~Exclusion Criteria:~* Any evidence of proliferative retinopathy (including Proliferative Diabetic Retinopathy (PDR) or other ischemic retinopathies involving vitreoretinal vascular proliferation) or exudative Age-Related Macular Degeneration (AMD) or retinal vein occlusion in the study eye.~* Subjects with any vitreous hemorrhage or any other vitreous opacification which precludes either of the following: visualization of the posterior pole by visual inspection OR adequate assessment of the macula by either OCT and/or fluorescein angiogram in the study eye.~* Subjects with macular hole diameter \> 400 μm in the study eye.~* Aphakia in the study eye.~* High myopia (more than 8D) in study eye (unless prior cataract extraction or refractive surgery that makes refraction assessment unreliable for myopia severity approximation, in which case axial length \>28 mm is an exclusion).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 125µg Ocriplasmin (Type: EXPERIMENTAL): 125µg intravitreal injection of ocriplasmin
- Placebo (Type: PLACEBO_COMPARATOR): placebo intravitreal injection

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Adalimumab in Axial Spondyloarthritis (ASIM) - MRI and Biomarkers in Patients With Spondyloarthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Spondyloarthritis (SpA) according to the new ASAS criteria for axial SpA~* BASDAI \> 40 mm despite NSAIDs~* Clinical indication for treatment with TNF-alpha inhibitor~* Age \> 18 years old and \< 85 years old~* Sufficient contraception for women~* Capable of giving informed consent~* Capable of complying with the examination program of the protocol~Exclusion Criteria:~* Pregnancy wish, pregnancy or breast-feeding~* DMARDs within 4 weeks prior to inclusion~* Oral, intra-articular or intramuscular glucocorticoid within 4 weeks prior to inclusion~* The use of other study drugs within 4 weeks prior to inclusion or less than 5 half-lives of the study drug before inclusion if this is more than 4 weeks~* The use of suspected disease-modifying or immunosuppressive drugs within 4 weeks prior to inclusion~* DMARDs are allowed during the study, but the dose cannot be changed from 4 weeks prior to inclusion through week~* Contraindications for TNF-α inhibitor treatment~* Contraindications for MRI~* Known recent drug or alcohol abuse~* Failure to provide written consent~* Incapable of complying with the examination program for physical or mental reasons

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): None
- Adalimumab (Type: ACTIVE_COMPARATOR): TNF-alpha inhibitor

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Tomato Products and Disease Risk

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female~* Between ages of 18-65~* BMI between 19 and 24 and hsCRP \< 1mg/L~* BMI between 25 and 35 and hsCRP \> 2.5mg/L~* No clinical evidence of cardiovascular, respiratory, renal, GI or hepatic disease~Exclusion Criteria:~* Pregnant and/or lactating~* allergies or intolerances to foods consumed in the study~* fasting blood glucose \> 110mg/dL~* taking OTC antioxidant supplements, prescription meds that may interfere with study endpoints~* unusual dietary habits~* actively trying to lose or gain weight~* addicted to drugs or alcohol~* medically documented psychiatric or neurological disturbances~* smoker (past smoker allowed if cessation \> 2 years)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Tomato (Type: ACTIVE_COMPARATOR): Tomato with high carb/fat meal
- Non-Tomato (Type: PLACEBO_COMPARATOR): Non-tomato with high carb/fat meal

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of BI 1356 (Linagliptin) Versus Placebo in Type 2 Diabetic Patients With Insufficient Glycemic Control

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Male or female patients with type 2 diabetes and insufficient glycaemic control.~* Age 18 or over and not older than 80 years~Exclusion criteria:~* Use of more than one oral antidiabetic agent within 10 weeks prior to informed consent, insulin, glitazones or GLP-1 analogues within 3 months.~* Myocardial infarction, stroke or transient ischaemic attack within 6 months prior to informed consent.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- linagliptin 5 mg (Type: EXPERIMENTAL): linagliptin 5 mg once daily
- placebo (Type: PLACEBO_COMPARATOR): placebo matching linagliptin 5 mg tablets

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Diphenhydramine Hydrochloride Effects in Subjects With Occasional Sleeplessness

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* be male or female subjects, ≥18 years of age to 55 years of age, who report that they are currently experiencing occasional sleeplessness characterized by difficulty initiating sleep (ie, taking ≥30 minutes to fall asleep) on average 2-4 times per week for less than 1 month;~* be in good general health without clinically significant disease (no previously diagnosed sleep disorders);~* if female, have a negative screening pregnancy test and agree to be on approved methods of birth control throughout the study~Exclusion Criteria:~* have a clinically significant illness within 30 days of Screening;~* are taking medication that could interfere with the study medication;~* have been under a clinician's care for insomnia treatment and control within the past year or has a history of insomnia or is currently taking prescription medications for insomnia;~* are currently taking medications known to effect sleep function;~* have current or past history of serious, severe or unstable physical or psychiatric illness;~* have current diagnosis of severe urinary retention;~* have current diagnosis of untreated narrow angle glaucoma;~* had participated in a clinical drug study or used an investigational new drug during the previous 30 days;~* have any clinically significant or abnormal finding in physical examination, vital signs, ECG, or clinical laboratory tests that may affect the subject's safety or outcome of the study;

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Diphenhydramine Hydrochloride (Type: EXPERIMENTAL): Diphenhydramine (50 mg) elixir taken when subjects had trouble falling asleep
- Placebo (Type: PLACEBO_COMPARATOR): Placebo elixir taken when subjects had trouble falling asleep

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Turoctocog Alfa in Previously Treated Male Children With Haemophilia A

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male patients with severe (baseline FVIII less than or equal to 1%) haemophilia A~* Age below 12 years and weight at least 11 kg~Exclusion Criteria:~* Surgery planned to occur during trial participation (exceptions are port placement, dental extractions, and minor, uncomplicated emergent procedures)~* Congenital or acquired coagulation disorders other than haemophilia A~* Any history of FVIII inhibitors (greater than or equal to 0.6 BU/mL)

- Gender: MALE
- Minimum Age: None
- Maximum Age: 11 Years
- Healthy Volunteers: f

Study Arms:
- rFVIII (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Chemotherapy Followed By Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory AIDS-Related Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Intermediate- or high-grade non-Hodgkin's lymphoma or Hodgkin's disease~  * Failed to achieve complete remission with initial therapy OR~ * Relapsed after initial therapy~* May be in complete remission after salvage therapy~* Sensitive to most recent chemotherapy~  * Improvement of at least 25% in bidimensional tumor measurements OR~ * Improvement in evaluable disease sustained over 4 weeks~* Measurable or evaluable disease~* HIV-1 positive~* CD4 greater than 50 cells/mm\^3 (unless not receiving optimal antiretroviral therapy)~* HIV RNA less than 110,000 copies/mL (unless not receiving optimal antiretroviral therapy)~* No active leptomeningeal or parenchymal CNS involvement NOTE: A new classification scheme for adult non-Hodgkin's lymphoma has been adopted by PDQ. The terminology of indolent or aggressive lymphoma will replace the former terminology of low, intermediate, or high grade lymphoma. However, this protocol uses the former terminology.~PATIENT CHARACTERISTICS:~Age:~* Physiologic 18 and over~Performance status:~* Karnofsky 70-100%~Life expectancy:~* Not specified~Hematopoietic:~* Absolute neutrophil count greater than 1,000/mm\^3~Hepatic:~* AST no greater than 3 times upper limit of normal~* Bilirubin no greater than 2.0 mg/dL (unless receiving indinavir)~Renal:~* Creatinine no greater than 2.0 mg/dL~Cardiovascular:~* No history of cardiac disease~* LVEF at least 45%~Pulmonary:~* No history of symptomatic pulmonary disease~* DLCO at least 60%~Other:~* No active opportunistic infections~* No cytomegalovirus retinitis or pneumonitis requiring maintenance therapy~* No sensitivity to E. coli-derived products~* Not pregnant~* Negative pregnancy test~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* Not specified~Chemotherapy:~* See Disease Characteristics~* At least 1 week since prior chemotherapy~Endocrine therapy:~* Not specified~Radiotherapy:~* Not specified~Surgery:~* Not specified~Other:~* Chronic suppressive therapy for infection allowed

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Long-Acting Reversible Contraception

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* 18 to 29 years of age;~* sexually active;~* seeking oral or injectable contraception;~* working cell phone;~* working email account;~* willingness to be contacted by the clinic staff or study coordinators; and,~* willingness to complete questionnaires.~Exclusion Criteria:~* currently pregnant;~* previous use of a long-acting reversible contraceptive (LARC) method; and,~* medical contraindications for oral contraceptives and injectables.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 29 Years
- Healthy Volunteers: t

Study Arms:
- Preference SARC (Type: OTHER): Participants received one of a variety of oral contraceptives or DMPA
- Randomized LARC (Type: EXPERIMENTAL): Participants receive one of the following interventions:~Implanon® or Nexplanon®; ParaGard®; Mirena®
- Randomized SARC (Type: ACTIVE_COMPARATOR): Participants received one of a variety of oral contraceptives or DMPA

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Intra-dermal With Topical Imiquimod Pretreatment Versus Intra-muscular Hepatitis B Vaccination in IBD Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adults aged over 18 years old~* Confirmed IBD diagnosis (Ulcerative colitis, Crohns disease or IBD-Unclassified)~* HBsAg -ve / anti-HBs / antiHBc -ve~* Subjects must give written informed consent~* Subjects must be available to complete the study and comply with study procedures~Exclusion Criteria:~* Inability or unwilling to follow all required study procedures~* History of allergy or severe adverse reaction to the study vaccines, their components, topical imiquimod or aqueous cream~* Pregnant or lactating women~* HBsAg / anti-HBs / anti-HBc +ve~* Confirmed hepatitis C virus (HCV) (anti-HCV +ve) infection~* Fever (axillary temperature ≥ 38°C or oral temperature ≥ 38.5°C within 3 days of intended study vaccination, subjects can be recruited after the febrile episode subsides~* Have an active neoplastic disease~* Have any condition which the investigator believes may prevent successful completion of the study or interfere with results of the study~* Received an experimental agent (vaccine, drug, biologic, medication) within 1 month prior to vaccination or expect to receive an experimental agent during the study period

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intradermal hepatitis B vaccine with imiquimod (Type: EXPERIMENTAL): Subjects in the study arm will receive 20 mcg intradermal Engerix-B at two separate sites (10 mcg/0.5 ml) with topical imiquimod ointment pre-treatment 5 minutes before injection.
- Intramuscular hepatitis B vaccine with aqueous cream (Type: ACTIVE_COMPARATOR): Subjects in the control arm will receive 20 mcg intramuscular Engerix-B at two separate sites (10 mcg/ 0.5 ml) with topical placebo aqueous cream pretreatment 5 minutes before injection.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Reducing Total Cardiovascular Risk in an Urban Community

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Currently receiving medical care at Johns Hopkins University~* African American or Caucasian and have diagnosed CVD, defined as a prior myocardial infarction, revascularization procedure for coronary disease, ischemic heart disease, stroke, or have diagnosed type 2 diabetes and not receiving any therapy~* Have either no LDL-C in their medical record during the 12 months prior to study entry or have an LDL greater than or equal to 100 mg/dl on or off lipid lowering pharmacotherapy~* Have either no blood pressure recorded in their medical record during the 12 months prior to study entry or a BP greater than 140/90 mmHg or greater than 130/80 mmHg if the participant is diabetic or has renal insufficiency~* If the participant is diabetic he or she has to either have no HbA1c recorded during the 12 months prior to study entry or HbA1c of 7 percent or greater~Exclusion criteria:~* A serious life-threatening noncardiac comorbidity with a life expectancy of less than 5 years~* A serious physician-recorded psychiatric morbidity that would interfere with the study~* Sufficient neurological impairment that would interfere with the study

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Comprehensive Intervention Group (Type: ACTIVE_COMPARATOR): The NP/CHW intervention focused on behavioral interventions to affect therapeutic lifestyle changes and adherence to medications and appointments as well as the prescription and titration of medications for one year. The NP and CHW worked as a team. The NP oversaw the initial assessment and, in collaboration with the CHW, tailored the intervention plan, conducted the intervention including lifestyle modification counseling and medication titration and prescription, consulted with the physician, and supervised the CHW. Specific algorithms for drug treatment of hyperlipidemia, hypertension (HBP), hyperglycemia, ACE, and β-blocker therapy were developed for this study based on current guidelines and standards of care.
- Less Intensive Intervention Group (Type: ACTIVE_COMPARATOR): Participants will receive usual care from their physicians and a Less Intensive (LI) intervention of feedback on cardiovascular disease (CVD) risk factors and guidelines to patients and their physicians. Patients and their providers in the received the results of baseline lipids, BP, and HbA1c along with the recommended goal levels and a pamphlet on controlling risk factors published by the American Heart Association. In addition, providers received copies of the AHA/ACC Guidelines for Secondary Prevention.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Nitrogen Bubble Detection After Simulated Dives in Divers With PFO and After PFO Closure

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. previously diagnosed PFO or a PFO that has been occluded by a catheter-based procedure~2. signed informed consent~Exclusion criteria:~1. another dive performed in the preceding 24 hours~2. another previously diagnosed right-to-left shunt~3. disagreement to be included in the study

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Patent foramen ovale dive A group (Type: None): Divers with a previously diagnosed patent foramen ovale observed after Dive A.
- Closure dive A group (Type: None): Divers with a patent foramen ovale previously closed by a catheter-based procedure observed after Dive A.
- patent foramen ovale dive B group (Type: None): Divers with a previously diagnosed patent foramen ovale observed after Dive B.
- closure dive B group (Type: None): Divers with a patent foramen ovale previously closed by a catheter-based procedure observed after Dive B.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Preventive PCI or Medical Therapy Alone for Vulnerable Atherosclerotic Coronary Plaque

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients aged ≥18 years~* Patients with suspected or known Coronary artery disease who are undergoing invasive cardiac catheterization~* Patients with at least one significant stenosis (diameter stenosis \>50%) with Fractional Flow Reserve (FFR) \>0.80 and meeting two of the following criteria:~  1. MLA(minimal luminal area)\<4mm2~ 2. Plaque burden\>70%~ 3. Large lipid-rich plaque on NIRS(Intracoronary Near-Infrared Spectroscopy), defined as MaxLCBI4mm\>315~ 4. TCFA(thin-cap fibroatheroma) defined as fibrous cap thickness \<65 μm and arc \>90° on optical coherence tomography (OCT) or ≥10% confluent necrotic core with \>30° abutting the lumen in three consecutive slices on Virtual-histology intravascular ultrasound (VH-IVUS)~* Eligible for percutaneous coronary intervention with Absorb Bioresorbable Vascular Scaffold or Everolimus Eluting Stent~* Reference vessel diameter 2.75-4.0~* Lesion length ≤ 40mm~* Willing and able to provide informed written consent~Exclusion Criteria:~* Patients for whom the preferred treatment is CABG(Coronary artery bypass grafting)~* Patients with stented lesions~* Patients with bypass graft lesions~* Patients with three or more target lesions~* Patients with two target lesions in the same coronary territory~* Patients with heavily calcified or angulated lesions~* Patients with bifurcation lesions requiring 2 stenting technique~* Patients with contraindications to or planned discontinuation of dual antiplatelet therapy within 1 year~* Patients with life expectancy \<2 years~* Patients with planned cardiac or major noncardiac surgery~* Woman who are breastfeeding, pregnant or planning to become pregnant during the course of the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Coronary intervention (Type: EXPERIMENTAL): bioabsorbable vascular scaffolds (BVS) (early period) or everolimus-eluting stents (middle and late period) +Optimal Medical Treatment
- Optimal Medical Treatment (Type: ACTIVE_COMPARATOR): Optimal Medical Treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete